Key facts
- This page summarizes David Diamond's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Jul 2021, 17:36.
David Diamond - 08 Jul 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)
- Reporting relationship
- Director
- Issuer ticker
- OTLC
- Reported as of
- 08 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2021, 17:36:50 UTC
- Next SEC filing
- 25 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Diamond
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Diamond filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 16 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OTLC
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +451,467
- Change %
- Price
- $0.000000
- Shares after
- 451,467
- Date
- 08 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 451,467
- Exercise price
- $0.1626
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.